UK Parkinson's Disease Consortium - UKPDC
- Principal Investigators
- Research Groups
- Cell Physiology
- Clinical Neuroscience
- Clinical Studies
- Drosophila Genetics
- Molecular Biology and Biochemistry
- Molecular Neuropathology
- Neurological Biochemistry
- Neurological Signalling
- Protein Phosphorylation
- Contact us
A study published in Brain, led by researchers
at UCL Institute of Neurology, has shown that genetic mutations which
cause a decrease in dopamine
production in the brain and lead to a form of childhood-onset Dystonia,
also play a role in the development of Parkinson’s disease.
The new Leonard Wolfson Experimental Neurology Centre (LWENC) has opened for clinical studies and trials
In this paper Claudia Manzoni studies how fibroblast
cells from people with Parkinson’s disease caused by mutations in LRRK2
react to starvation. Although the changes are quite subtle, there are
differences between the way that fibroblasts that contain mutant LRRK2
respond to being starved – suggesting that there may be changes in the
way that these cells regulate a key process called autophagy (a term
which comes from the greek meaning to eat yourself, and is one of the
ways that cells get rid of waste and recycle proteins and organellles).
Research led by consortium researchers Dr Helene Plun-Favreau (UCL Institute of Neurology) and Dr Alex Whitworth (University of Sheffield), and collaborator Dr Heike Laman (University of Cambridge), has discovered how genetic mutations linked to Parkinson’s disease might play a key role in the death of brain cells, potentially paving the way for the development of more effective drug treatments. In the new study, published in Nature Neuroscience, the team of cross-institutional researchers showed how defects in the Parkinson’s gene Fbxo7 cause problems with mitophagy. More...
Mutations in LRRK2 are the most common genetic cause of Parkinson’s disease. Here, Claudia Manzoni talks about her research (funded by the Rosetrees Trust and the Michael J. Fox Foundation) into what LRRK2 might be doing within the cell: Parkinson’s disease is a brain illness that afflicts 1 in 500 people in the UK. High profile patients, such as the actor Michael J Fox, the boxer Muhammad Ali and the late Pope John Paul II, have raised public awareness of Parkinson’s and its devastating impact. More...
Raquel Duran Ogalla
(Former Clinical Research Fellow)
I graduated in Biochemistry at University of Granada (Spain) in 2003. During the last year I became interested in the molecular pathways underlie the neurodegenerative diseases. After I finished my B.Sc., I got the Certificate of Educational Aptitude in 2004, and I joined the department of Physiology in the Faculty of Medicine of Granada, within the research group “Study of the Neurodegenerative diseases in Andalusia” lead by Professor Francisco Vives. For my PhD project I worked analysing blood markers of oxidative stress and protein impairment as well as their association with the clinical features in patients with Parkinson’s disease. To enlarge my knowledge in this field I attended a M.S. degree in Neuroscience at the Institute of Neurosciences, engaging this research work with my work thesis and getting the PhD in December 2008. Then, I continued working at the Institute of Neurosciences in the Biomedical Research Centre of the University of Granada as associate research fellow until August 2010. During this time, I focused on the role of several proteases in the pathogenesis of Huntington’s disease. In September 2010 I joined the Department of Molecular Neuroscience at the UCL as a postdoctoral research fellow under the supervision of Professor John Hardy, working on the study of new genetic variants confer risk to develop Parkinson’s disease.
Page last modified on 20 mar 13 16:39